Triazolone Antiviral Compounds for Resistant HIV
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral therapies for HIV, particularly non-nucleoside reverse transcriptase inhibitors (NNRTIs), face challenges such as rapid emergence of drug-resistant strains and adverse reactions, necessitating the development of safer compounds effective against both wild-type and resistant HIV strains.
Innovation Solution
Development of novel triazolone compounds with enhanced pharmacokinetic properties, including specific modifications to improve bioavailability and efficacy against resistant HIV strains, which can be administered alone or in combination with other antiviral agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-nucleoside reverse transcriptase inhibitors (NNRTIs) are used to treat HIV, then viral replication is inhibited, but drug-resistant strains emerge rapidly
Solution Approach 1:
The patent modifies the chemical structure of NNRTI compounds by changing parameters such as substituting hydrogen atoms with fluorine, chlorine, or bromine atoms, and modifying the heterocyclic ring structures. These parameter changes create new compounds with altered binding properties to the reverse transcriptase enzyme, effectively combating drug-resistant strains while maintaining inhibitory activity against viral replication.
2Reliability
If NNRTIs are administered to inhibit HIV reverse transcriptase, then viral replication is suppressed, but adverse reactions occur
Solution Approach 1:
The patent introduces specific substituent groups at particular positions on the NNRTI molecular structure (e.g., fluorine at position 2, chlorine at position 6). These localized modifications improve the compound's selectivity for the viral reverse transcriptase enzyme while reducing interaction with human cellular targets, thereby maintaining antiviral efficacy while minimizing adverse reactions.
3Productivity
If existing NNRTIs are used to treat HIV, then initial viral load reduction is achieved, but resistance develops with single point mutations
Solution Approach 1:
The patent creates composite molecular structures by combining multiple heterocyclic rings (pyridine, pyrimidine, triazine) with various substituent groups. This composite approach generates compounds with enhanced binding affinity and specificity to the reverse transcriptase enzyme, requiring multiple mutations rather than single point mutations to develop resistance, thus improving long-term treatment effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified triazolone compounds achieve higher blood levels and improved absorption, effectively inhibiting HIV reverse transcriptase, including strains resistant to existing NNRTIs, thereby providing a safer and more effective treatment option.
Implementation Method 1
non-nucleoside reverse transcriptase inhibitors for treating Human Immunodeficiency Virus (HIV) mediated diseases
Data Source
AI summary
The present invention relates to a method of treating an HIV-I infection with a compound according to formula I where R1, R2, R3, R4, R5, are as defined herein.